

<u>Subject:</u>	<b>Posterior Segment Optical Coherence Tomography</b>	<u>Publish Date:</u>	<b>12/18/2019</b>
<u>Guideline #:</u>	<b>CG-MED-85</b>	<u>Last Review Date:</u>	<b>11/07/2019</b>
<u>Status:</u>	<b>New</b>		

## Description

**This document addresses optical coherence tomography of the posterior segment of the eye. Posterior segment ocular structures include the choroid, optic nerve, macula, retina, and vitreous.**

## Clinical Indications

### Medically Necessary:

**Initial optical coherence tomography of the posterior segment of the eye is considered medically necessary for any of the following:**

- **To establish a diagnosis of a condition affecting the optic nerve or retina (including, but not limited to glaucoma, optic neuropathy, macular degeneration, diabetic retinopathy, macular edema, atrophy associated with degenerative retinal diseases), when a clinical diagnosis is uncertain; or**
- **To establish a baseline prior to treatment of a condition affecting the optic nerve or retina.**

**Repeat optical coherence tomography of the posterior segment of the eye is considered medically necessary to monitor a condition affecting the optic nerve or retina when there is documentation that changes detected on imaging (based on the anticipated clinical progression of the underlying disease) are likely to impact management; for example:**

- **To monitor for disease progression in individuals with glaucoma; or**
- **To manage retinal conditions undergoing active treatment (such as wet age-related macular degeneration, choroidal neovascularization, macular edema, diabetic retinopathy [proliferative and**

**This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.**

**Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.**

**Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.**

**No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.**

## Posterior Segment Optical Coherence Tomography

nonproliferative], branch retinal vein occlusion, central retinal vein occlusion, and cystoid macular edema) (that is: used for therapeutic decision making based on the individual's treatment protocol and clinical response as documented in the medical record); or

- To monitor for development of retinopathy for individuals receiving long-term use of chloroquine or hydroxychloroquine.

### Not Medically Necessary:

Initial and repeat optical coherence tomography of the posterior segment of the eye is considered not medically necessary when the above criteria are not met and for all other indications including, but not limited to multiple sclerosis and amyloidosis.

### Coding

*The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.*

#### CPT

92133

Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; optic nerve

92134

Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina

#### ICD-10 Diagnosis

E08.311-E08.3599

Including, but not limited to, the following:

Diabetes mellitus due to underlying condition with ophthalmic complications

E09.311-E09.3599

Drug or chemical induced diabetes mellitus with ophthalmic complications

E10.311-E10.3599

Type 1 diabetes mellitus with ophthalmic complications

E11.311-E11.3599

Type 2 diabetes mellitus with ophthalmic complications

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

<u>E13.311-E13.3599</u>	<b>Other specified diabetes mellitus with ophthalmic complications</b>
<u>H30.001-H36</u>	<b>Disorders of choroid and retina</b>
<u>H40.001-H40.9</u>	<b>Glaucoma</b>
<u>H46.00-H46.9</u>	<b>Optic neuritis</b>
<u>H47.011-H47.299</u>	<b>Disorders of optic nerve, papilledema, optic atrophy</b>
<u>T37.2X5A-T37.2X5S</u>	<b>Adverse effect of antimalarials and drugs acting on other blood protozoa</b>
<u>Z01.00-Z01.021</u>	<b>Encounter for examination of eyes and vision</b>

### Discussion/General Information

**Optical coherence tomography (OCT) is a non-invasive imaging test that uses light waves to take cross-section pictures of the retina. It shows each of the retina's distinctive layers which allows an ophthalmologist to map and measure their thickness. These measurements help with diagnosis and provide treatment guidance for glaucoma and diseases of the retina such as age-related macular degeneration and diabetic eye disease.**

**According to the American Academy of Ophthalmology Preferred Practice Pattern® for Diabetic Retinopathy (2017), optical coherence tomography can be used to quantify thickness of the retina, monitor macular edema, and find other forms of macular diseases in those individuals with diabetic macular edema. Optical coherence tomography can direct treatment decisions such as continuing medications, changing of medications, or initiating surgery.**

**The American Academy of Ophthalmology also has a Preferred Practice Pattern for Age-Related Macular Degeneration (2015) in which they state that the use of optical coherence tomography is able to define the cross-sectional architecture of the retina. The use of optical coherence tomography can detect the presence of fluid that cannot be found on biomicroscopy alone. Evaluation of the retina by looking at structural changes helps to guide and evaluate response to treatment. The frequency of repeat imaging of individuals undergoing active treatment should consider the treatment protocol and likelihood for a clinical change. For example, OCT imaging twice a year may be appropriate for neurologic conditions such as glaucoma as nerve problems proceed slowly and over time. In individuals with wet age-related macular degeneration treated**

**This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.**

**Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.**

**Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.**

**No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.**

## Posterior Segment Optical Coherence Tomography

**with antiangiogenic drugs, OCT may be utilized at a higher frequency when used for therapeutic decision making based on the treatment protocol and response. Other conditions that undergo rapid clinical changes monthly requiring aggressive therapy and frequent follow-up (for example, macular hole and traction retinal detachment) may also require more frequent scans.**

**Repeat OCT of the posterior segment of the eye may be appropriate in monitoring other conditions affecting the optic nerve or retina if changes detected on imaging are likely to impact management. For example, the role of OCT has been proposed as a method in monitoring vitreoretinal interface abnormalities for disease progression (to determine eligibility for surgical treatment), and in monitoring retinoschisis for development of non-acute retinal detachment.**

**Chloroquine and hydroxychloroquine are medications primarily used for the treatment of malaria. They are known to cause a mild suppression of the immune system and have been used for treating connective tissue disorders in some autoimmune disorders such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and some dermatological and inflammatory diseases. One notable side effect with the use of these medications is the potential risk for the development of retinopathy. The American Academy of Ophthalmology (Marmor, 2016) has recommendations about chloroquine and hydroxychloroquine retinopathy. The risk of toxicity depends on daily dose and duration of use. Screening recommendations include a baseline ophthalmologic exam within a year of starting chloroquine or hydroxychloroquine. If maculopathy is present at the baseline screening, the recommendation is to add visual fields and optical coherence tomography. Following 5 years of use of medication, annual screening should begin, sooner in the presence of major risk factors (that is, renal disease, macular disease, duration of use of greater than 5 years, concomitant use of tamoxifen).**

### **Definitions**

**Branch retinal vein occlusion: An occlusion near the retina in a branch retinal vein.**

**Central retinal vein occlusion: An occlusion of the central retinal vein where it enters the eye.**

**This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.**

**Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.**

**Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.**

**No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.**

**Choroidal neovascularization: The formation of new blood vessels in the choroid layer of the eye.**

**Diabetic retinopathy: The progressive damage to the blood vessels in the back of the eye.**

**Glaucoma: A grouping of diseases that can damage the optic nerve and result in vision loss and blindness.**

**Macular degeneration: Loss of central vision when the part of the retina called the macula is damaged.**

**Macular edema: Occurs when there is a build-up of fluid in the retina which can lead to swelling and vision distortion.**

**Optic neuropathy: Damage to the optic nerve.**

## References

### Peer Reviewed Publications:

1. Eibenberger K, Sacu S, Rezar-Dreindl S, et al. Monitoring retinoschisis and non-acute retinal detachment by optical coherence tomography: morphologic aspects and clinical impact. *Acta Ophthalmol.* 2017; 95(7):710-716.
2. Levison AL, Kaiser PK. Vitreomacular interface diseases: diagnosis and management. *Taiwan Journal of Ophthalmology.* 2014; 4(2):63-68.
3. Marmor MF, Kellner U, Lai TY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). *Ophthalmology.* 2016; 123(6):1386-1394.

### Government Agency, Medical Society, and Other Authoritative Publications:

1. American Academy of Ophthalmology. Preferred Practice Patterns. For additional information visit the AAO website: <https://www.aao.org/>. Accessed on September 6, 2019
  - Age-Related Macular Degeneration (2015).
  - Diabetic Retinopathy (2017).

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

### Index

### Optical Coherence Tomography

### History

<u>Status</u>	<u>Date</u>	<u>Action</u>
<u>New</u>	<u>11/07/2019</u>	<u>Medical Policy &amp; Technology Assessment Committee (MPTAC) review.</u> <u>Initial document development.</u>

This Clinical UM Guideline is intended to provide assistance in interpreting Healthy Blue's standard Medicaid benefit plan. When evaluating insurance coverage for the provision of medical care, federal, state and/or contractual requirements must be referenced, since these may limit or differ from the standard benefit plan. In the event of a conflict, the federal, state and/or contractual requirements for the applicable benefit plan coverage will govern. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Clinical UM Guideline is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to implement a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan's or line of business's members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.